MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-23-2026
West Pharmaceutical Services Interest Expense 2011-2026 | WST
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense West Pharmaceutical Services
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 M | -1 M | 3 M | -51.3 M | 8.2 M | 8.2 M | 8.5 M | 8.4 M | 7.8 M | 8.1 M | 14.1 M | 16.5 M | 17 M | 16.7 M | 18.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.2 M | -51.3 M | 5.43 M |
Quarterly Interest Expense West Pharmaceutical Services
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -200 K | - | -200 K | -200 K | -200 K | - | -700 K | - | 1.6 M | - | 2.9 M | 100 K | 2.2 M | - | 2.2 M | 1.8 M | 2.2 M | - | 1.8 M | 1.9 M | 1.9 M | - | 2.1 M | 2 M | 2 M | - | 2.1 M | 2 M | 2.3 M | - | 2 M | 2.2 M | 1.9 M | - | 1.4 M | 2.2 M | 2.1 M | - | 2.2 M | 2 M | 2.5 M | - | 3.7 M | 3.4 M | 4.1 M | - | 4.5 M | 4.2 M | 4 M | - | 4.4 M | 4.1 M | 4.6 M | - | 4.4 M | 4.6 M | 4.3 M | - | 4.5 M | 4.6 M | 4.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.7 M | -700 K | 2.49 M |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
-16.4 M | $ 59.77 | -1.01 % | $ 11.9 B |  USA |
 |
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | USA |
 |
iRhythm Technologies
IRTC
|
5.44 M | $ 114.71 | 0.48 % | $ 3.67 B | USA |
 |
ICU Medical
ICUI
|
93.3 M | $ 118.86 | -3.36 % | $ 2.93 B | USA |
 |
Repro Med Systems
KRMD
|
9.91 K | $ 3.93 | -1.26 % | $ 182 M | USA |
 |
LeMaitre Vascular
LMAT
|
5.18 M | $ 96.95 | -2.56 % | $ 2.19 B | USA |
 |
Alcon
ALC
|
204 M | $ 63.77 | -0.39 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
300 K | $ 178.41 | 0.03 % | $ 9.51 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-26 K | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
-2.3 M | $ 23.53 | -1.34 % | $ 3.95 B | USA |
 |
electroCore
ECOR
|
14.9 K | $ 6.0 | -6.69 % | $ 50.9 K | USA |
 |
Haemonetics Corporation
HAE
|
-9.75 M | $ 56.46 | -1.16 % | $ 2.84 B | USA |
 |
STAAR Surgical Company
STAA
|
2.25 M | $ 32.48 | 1.47 % | $ 1.61 B | USA |
 |
STERIS plc
STE
|
8.4 M | $ 211.95 | -1.87 % | $ 20.9 B | USA |
 |
Isoray
ISR
|
84 K | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
13.6 M | $ 142.49 | 0.23 % | $ 6.9 B | USA |
 |
Teleflex Incorporated
TFX
|
85.1 M | $ 130.03 | -0.19 % | $ 5.8 B | USA |
 |
InfuSystem Holdings
INFU
|
2 K | $ 8.69 | 0.93 % | $ 180 M | USA |
 |
Microbot Medical
MBOT
|
-5 K | $ 1.89 | 1.89 % | $ 86.5 M |  Israel |
 |
Milestone Scientific
MLSS
|
60.3 K | $ 0.33 | -2.89 % | $ 27.1 M | USA |
 |
Merit Medical Systems
MMSI
|
-2.39 M | $ 61.38 | -1.89 % | $ 3.63 B | USA |
 |
Utah Medical Products
UTMD
|
-120 K | $ 63.27 | -0.68 % | $ 205 M | USA |
 |
Pulse Biosciences
PLSE
|
-52 K | $ 24.3 | -10.33 % | $ 1.64 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
24 M | $ 9.96 | -4.32 % | $ 1.99 B | USA |
 |
Retractable Technologies
RVP
|
227 K | $ 0.67 | -3.06 % | $ 20.1 M | USA |
 |
Pro-Dex
PDEX
|
533 K | $ 59.69 | 1.77 % | $ 196 M | USA |
 |
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
1.82 M | $ 20.35 | -3.37 % | $ 972 M | USA |
 |
Stereotaxis
STXS
|
2 K | $ 1.88 | -3.6 % | $ 171 M | USA |
 |
Baxter International
BAX
|
290 M | $ 17.3 | -2.76 % | $ 8.87 B | USA |
 |
ResMed
RMD
|
3.2 M | $ 202.01 | -0.22 % | $ 29.5 B | USA |
 |
AtriCure
ATRC
|
683 K | $ 27.98 | -0.6 % | $ 1.34 B | USA |
 |
Harvard Bioscience
HBIO
|
-2.66 M | $ 5.26 | -4.71 % | $ 233 M | USA |
 |
AngioDynamics
ANGO
|
4.94 M | $ 10.84 | -1.72 % | $ 443 M | USA |
 |
Becton, Dickinson and Company
BDX
|
613 M | $ 143.06 | -0.98 % | $ 41.2 B | USA |
 |
Nephros
NEPH
|
-78 K | $ 3.17 | -5.11 % | $ 33.6 M | USA |
 |
OraSure Technologies
OSUR
|
229 K | $ 3.07 | 3.9 % | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
2.82 M | $ 104.6 | 1.18 % | $ 5.88 M | USA |